{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T16:13:44Z","timestamp":1788106424462,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015438","name":"International Society on Thrombosis and Haemostasis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtha.2025.02.026","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T23:41:45Z","timestamp":1741304505000},"page":"2060-2066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: communication from the ISTH SSC Subcommittee on Control of Anticoagulation"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-4738","authenticated-orcid":false,"given":"Nicolas","family":"Gendron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1322-9368","authenticated-orcid":false,"given":"Lana A.","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.02.026_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/CIRCULATIONAHA.117.033326","article-title":"Management of intraprocedural anticoagulation in patients on non-vitamin K antagonist oral anticoagulants undergoing catheter ablation for atrial fibrillation: understanding the gaps in evidence","volume":"138","author":"Martin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.02.026_bib2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3390\/jcm9020350","article-title":"Activated clotting time monitoring during atrial fibrillation catheter ablation: does the anticoagulant matter?","volume":"9","author":"Martin","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.02.026_bib3","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1053\/j.jvca.2016.09.002","article-title":"Impact of the direct oral anticoagulants on activated clotting time","volume":"31","author":"Dincq","year":"2017","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2025.02.026_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.02.026_bib5","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.026_bib6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.026_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1538-7836.2010.04098.x","article-title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays","volume":"9","author":"Hillarp","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.026_bib8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jth.12649","article-title":"Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays","volume":"12","author":"Hillarp","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.026_bib9","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2146\/ajhp150596","article-title":"Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions","volume":"73","author":"Faust","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jtha.2025.02.026_bib10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.026_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ijlh.13342","article-title":"Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory","volume":"43","author":"Siriez","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.026_bib12","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3390\/ijms23031821","article-title":"Inherited thrombophilia in the era of direct oral anticoagulants","volume":"23","author":"Khider","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.02.026_bib13","first-page":"e113","article-title":"groupe de travail Recommandations de bonne pratique pour la prise en charge de la MVTE. Who should supervise anticoagulant treatment and how?","volume":"38","author":"Smadja","year":"2019","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.jtha.2025.02.026_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.02.026_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.chest.2017.09.047","article-title":"Are screening tests reliable to rule out direct oral anticoagulant plasma levels at various thresholds (30, 50, or 100 ng\/mL) in emergency situations?","volume":"153","author":"Jabet","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.02.026_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5853\/jos.2022.03034","article-title":"Practical nomogram predicting apixaban or rivaroxaban concentrations from low-molecular-weight heparin anti-Xa values: special interest in acute ischemic stroke patients","volume":"25","author":"Brakta","year":"2023","journal-title":"J Stroke"},{"key":"10.1016\/j.jtha.2025.02.026_bib17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1213\/ANE.0000000000005114","article-title":"Heparin anti-Xa activity, a readily available unique test to quantify apixaban, rivaroxaban, fondaparinux, and danaparoid levels","volume":"132","author":"Boissier","year":"2021","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2025.02.026_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2022.05.005","article-title":"Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels","volume":"215","author":"Mithoowani","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.026_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1060028018811657","article-title":"Anti-Xa oral anticoagulant plasma concentration assay in real life: rivaroxaban and apixaban quantification in emergency with LMWH calibrator","volume":"53","author":"Billoir","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2025.02.026_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40495-020-00232-7","article-title":"Overview and practical application of coagulation assays in managing anticoagulation with direct oral anticoagulants (DOACs)","volume":"6","author":"Rimsans","year":"2020","journal-title":"Curr Pharmacol Rep"},{"key":"10.1016\/j.jtha.2025.02.026_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2017.05.024","article-title":"Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels","volume":"156","author":"Sabor","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.026_bib22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1160\/TH10-05-0328","article-title":"Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay","volume":"104","author":"Barrett","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.026_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11239-011-0591-8","article-title":"Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban\u2014an oral, direct and selective factor Xa inhibitor","volume":"32","author":"Becker","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.02.026_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1076029616629759","article-title":"Evaluation of a heparin-calibrated antifactor Xa assay for measuring the anticoagulant effect of oral direct Xa inhibitors","volume":"22","author":"Beyer","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.02.026_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ijlh.12974","article-title":"An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays","volume":"41","author":"Cini","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.026_bib26","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.02.026_bib27","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/eurheartj\/ehx403","article-title":"Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study","volume":"38","author":"Godier","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.02.026_bib28","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/bloodadvances.2020002335","article-title":"Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure","volume":"4","author":"Shaw","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.02.026_bib29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/ijlh.14321","article-title":"DOAC-remove to counteract the interference of anti-Xa oral anticoagulants on the monitoring of heparin","volume":"6","author":"Melicine","year":"2024","journal-title":"Int J Lab Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.02.026_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ijlh.13585","article-title":"Review of coagulation preanalytical variables with update on the effect of direct oral anticoagulants","volume":"43","author":"Gosselin","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.026_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12959-023-00501-7","article-title":"The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review","volume":"21","author":"Frackiewicz","year":"2023","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2025.02.026_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ijlh.13703","article-title":"Study of in vitro thrombin generation after neutralization of heparin","volume":"44","author":"Hardy","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.026_bib33","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1093\/ajhp\/zxaa143","article-title":"Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: a retrospective review","volume":"77","author":"Smith","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jtha.2025.02.026_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ajcp\/aqab135","article-title":"From activated partial thromboplastin time to antifactor Xa and back again","volume":"157","author":"May","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2025.02.026_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1060028017729481","article-title":"Influence of direct oral anticoagulants on anti-factor Xa measurements utilized for monitoring heparin","volume":"52","author":"Macedo","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2025.02.026_bib36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/phar.2444","article-title":"The relationship between the initial anti-factor Xa measurement and the duration of direct oral anticoagulant influence in patients transitioning to heparin","volume":"40","author":"Plum","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2025.02.026_bib37","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/jth.14806","article-title":"Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors","volume":"18","author":"Stuart","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.026_bib38","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1177\/10600280221090211","article-title":"Comparison of managing factor Xa inhibitor to unfractionated heparin transitions by aPTT versus a treatment guideline utilizing heparin anti-Xa levels","volume":"56","author":"Dingus","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2025.02.026_bib39","doi-asserted-by":"crossref","first-page":"e1206","DOI":"10.1097\/CCM.0000000000005179","article-title":"Prevalence and clinical impact of reduced coagulation factor XII activity in patients receiving extracorporeal membrane oxygenation","volume":"49","author":"Buchtele","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtha.2025.02.026_bib40","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/jth.13138","article-title":"The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders","volume":"13","author":"Jacquemin","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.026_bib41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hae.13930","article-title":"Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: a comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects","volume":"26","author":"Favaloro","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.02.026_bib42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.thromres.2024.04.005","article-title":"French Society on Thrombosis and Haemostasis. Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?","volume":"237","author":"Gendron","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.026_bib43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/bjh.16091","article-title":"A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-remove","volume":"187","author":"Cox-Morton","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.02.026_bib44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2019.11.001","article-title":"Potential usefulness of activated charcoal (DOAC remove\u00ae) for dRVVT testing in patients receiving direct oral anticoagulants","volume":"184","author":"Jourdi","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.026_bib45","unstructured":"BIOPHENTM ANTI-IIa (2 stages heparin assay). Aniara Diagnostica. https:\/\/www.aniara.com\/PROD\/a220005.html. [accessed March 24, 2025]."}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:10:46Z","timestamp":1780279846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1538783625001254"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.026","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: communication from the ISTH SSC Subcommittee on Control of Anticoagulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}